

Long-term protection from HIV infection with oral HIV
bisexual men: findings from the expanded and extended
implementation study

Lancet HIV, the

8, e486-e494

DOI: [10.1016/s2352-3018\(21\)00074-6](https://doi.org/10.1016/s2352-3018(21)00074-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	HIV testing in COVID-19 pandemic and beyond in Japan. <i>Global Health & Medicine</i> , 2021, 3, 356-357.	1.4	5
2	Overcoming barriers to HIV pre-exposure prophylaxis (PrEP) coverage in Australia among Medicare-ineligible people at risk of HIV: results from the MI-EPIC clinical trial. <i>Sexual Health</i> , 2022, 18, 453-459.	0.9	8
3	Assessing the Information-Motivation-Behavioral Skills Model to Predict Pre-exposure Prophylaxis Adherence Among Black Men Who have Sex with Men and Transgender Women in a Community Setting in New York City. <i>AIDS and Behavior</i> , 2022, 26, 2494-2502.	2.7	8
4	Higher sexually transmissible infection test yield among men who have sex with men attending a community-based testing site compared with a clinical service in Sydney, Australia. <i>Sexually Transmitted Diseases</i> , 2022, Publish Ahead of Print, .	1.7	0
5	Incorrect Knowledge of Event-Driven PrEP 2-1-1 Dosing Regimen Among PrEP-Experienced Gay and Bisexual Men in Australia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 132-139.	2.1	5
6	COVID-19 Vaccine Uptake and Its Impacts in a Cohort of Gay and Bisexual Men in Australia. <i>AIDS and Behavior</i> , 2022, 26, 2692-2702.	2.7	10
7	A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 762-766.	1.7	8
8	Barriers to accessing HIV pre-exposure prophylaxis for Medicare-ineligible people in Melbourne, Australia: analysis of patients attending the PrEPMe Clinic. <i>Medical Journal of Australia</i> , 2022, 216, 320-321.	1.7	3
9	Promises and challenges: cabotegravir for preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 186-191.	3.8	7
10	HIV Pre-exposure Prophylaxis Uptake and Continuation Among Key Populations in Cameroon: Lessons Learned From the CHAMP Program. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 91, 39-46.	2.1	6
11	Assessing the impact of HIV pre-exposure prophylaxis scale-up on gonorrhoea incidence among gay and bisexual men in Sydney: a mathematical modelling study. <i>Sexually Transmitted Diseases</i> , 0, Publish Ahead of Print, .	1.7	0
12	Approaches to forecasting of time dynamics of the processes and use of Farr's epidemic evolution law on example of dynamics of new cases of HIV-infection in Russian Federation. <i>HIV Infection and Immunosuppressive Disorders</i> , 2022, 14, 90-99.	0.3	0
13	Prescribing as affective clinical practice: Transformations in sexual health consultations through HIV pre-exposure prophylaxis. <i>Sociology of Health and Illness</i> , 2022, 44, 1182-1200.	2.1	7
14	Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study. <i>Lancet Public Health</i> , The, 2022, 7, e529-e536.	10.0	25
15	Switching to Non-daily Pre-exposure Prophylaxis Among Gay and Bisexual Men in Australia: Implications for Improving Knowledge, Safety, and Uptake. <i>Sexuality Research and Social Policy</i> , 2022, 19, 1979-1988.	2.3	5
16	Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS) Tj ETQq1 1 0,784314 rgBT /Overd	4.7	48
17	Scaling up preexposure prophylaxis to maximize HIV prevention impact. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 173-178.	3.8	12
18	Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 199-204.	3.8	1

#	ARTICLE	IF	CITATIONS
19	Is non-occupational HIV Post Exposure Prophylaxis (nPEP) still used? An exploration of nPEP use since widespread availability of HIV PrEP. <i>International Journal of STD and AIDS</i> , 0, , 095646242211165.	1.1	0
20	Adjusting Behavioural Surveillance and Assessing Disparities in the Impact of COVID-19 on Gay and Bisexual Men's HIV-Related Behaviour in Australia. <i>AIDS and Behavior</i> , 2023, 27, 518-534.	2.7	11
21	Characteristics of HIV seroconversions in a large prospective implementation cohort study of oral HIV pre-exposure prophylaxis in men who have sex with men (EPIC-NSW). <i>Clinical Infectious Diseases</i> , 0, , .	5.8	1
22	The Impact of Providing Free HIV Self-testing on Sexual Risk Behaviors Among Men who have Sex with Men in Hunan, China: A Randomized Controlled Trial. <i>AIDS and Behavior</i> , 2023, 27, 708-718.	2.7	4
23	Roll-out of HIV pre-exposure prophylaxis use in France: A nationwide observational study from 2016 to 2021. <i>Lancet Regional Health - Europe</i> , The, 2022, 22, 100486.	5.6	8
24	Pre-Exposure Prophylaxis for HIV Infection as a Public Health Tool. <i>Journal of Law, Medicine and Ethics</i> , 2022, 50, 24-28.	0.9	5
25	Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic. <i>Journal of Law, Medicine and Ethics</i> , 2022, 50, 8-23.	0.9	19
26	Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany. <i>Infection</i> , 2023, 51, 665-678.	4.7	6
27	Pre-exposure prophylaxis for HIV: effective and underused. <i>Cmaj</i> , 2022, 194, E1164-E1170.	2.0	0
28	Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 3427-3435.	3.0	1
29	Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?. <i>HIV Medicine</i> , 2023, 24, 653-663.	2.2	5
30	Characterizing the Impact of the COVID-19 Pandemic on HIV PrEP care: A Review and Synthesis of the Literature. <i>AIDS and Behavior</i> , 2023, 27, 2089-2102.	2.7	6
31	Discontinuation of government subsidized HIV pre-exposure prophylaxis in Australia: a whole-of-population analysis of dispensing records. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	3
33	Factors Associated With Willingness to Use Daily Antibiotics as Sexually Transmitted Infection Prophylaxis Among HIV Preexposure Prophylaxis-Experienced Gay and Bisexual Men in Australia. <i>Sexually Transmitted Diseases</i> , 2023, 50, 144-149.	1.7	1
34	Multi-dimensional mismatch and barriers for promoting PrEP among men who have sex with men in China: a cross sectional survey from the Demand-side. <i>AIDS Research and Therapy</i> , 2023, 20, .	1.7	1
35	Identifying Patterns of Discontinuing and Recommencing Pre-exposure Prophylaxis in the Context of Sexual Behavior Among Gay and Bisexual Men in Australia. <i>AIDS and Behavior</i> , 0, , .	2.7	0
36	HIV-Related Knowledge and Practices among Asian and African Migrants Living in Australia: Results from a Cross-Sectional Survey and Qualitative Study. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4347.	2.6	1
37	Attitudes Towards Treatment as Prevention Among PrEP-Experienced Gay and Bisexual Men in Australia. <i>AIDS and Behavior</i> , 2023, 27, 2969-2978.	2.7	1

#	ARTICLE	IF	CITATIONS
38	Enzyme-triggered peptide hydrogels as a long-acting injectable platform for systemic delivery of HIV/AIDS drugs. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	5
39	Human Immunodeficiency Virus Seroconversion Among Men Who Have Sex With Men Who Use Event-Driven or Daily Oral Pre-Exposure Prophylaxis (CohMSM-PrEP): A Multi-Country Demonstration Study From West Africa. <i>Clinical Infectious Diseases</i> , 2023, 77, 606-614.	5.8	6
40	Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study. <i>JMIR Public Health and Surveillance</i> , 0, 9, e44961.	2.6	2
42	The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities. <i>Lancet HIV</i> , 2023, 10, e404-e411.	4.7	11
44	Preparing for long-acting PrEP delivery: building on lessons from oral PrEP. <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	3
45	Understanding how PrEP is made successful: Implementation science needs an evidence-making approach. <i>Global Public Health</i> , 2023, 18, .	2.0	1
46	Pre-Exposure Prophylaxis and HIV Incidence. <i>B E Journal of Economic Analysis and Policy</i> , 2023, 23, 1163-1173.	0.9	0
47	Variations in HIV Prevention Coverage in Subpopulations of Australian Gay and Bisexual Men, 2017-2021: Implications for Reducing Inequities in the Combination Prevention Era. <i>AIDS and Behavior</i> , 0, , .	2.7	0
48	Physical and mental health of long-term users of HIV pre-exposure prophylaxis (PrEP) in Australia: The X-PLORE Cohort. <i>Aids</i> , 0, , .	2.2	0
49	Trends in illicit drug use and their association with HIV transmission risks from behavioural surveillance of Australian gay and bisexual men. <i>Drug and Alcohol Review</i> , 2024, 43, 539-550.	2.1	0
50	Projected Life Expectancy Gains From Improvements in HIV Care in Black and White Men Who Have Sex With Men. <i>JAMA Network Open</i> , 2023, 6, e2344385.	5.9	0
51	HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment. <i>Lancet HIV</i> , 2023, 10, e790-e806.	4.7	2
54	Cost-effectiveness of the expansion of PrEP for HIV infection in the Asia Pacific region. <i>The Lancet Global Health</i> , 2024, 12, e177-e178.	6.3	0